Sentiment Trading

CNS Pharmaceuticals Inc, a biotech company based in Houston, Texas, is working to develop groundbreaking treatments for brain tumors, offering hope to patients worldwide despite facing financial challenges in the industry.

CNS Pharmaceuticals Inc’s stock has surged 73% to $2.10, driven by a $5 million public offering and advancements in drug development, including the acquisition of Orphan Drug Designation for its novel abeotaxane TPI 287.